Neurourology - Grand Journal of Urology

Neurourology

Original Article

Grand J Urol 2024;4(1):006-011, DOI: 10.5505/GJU.2024.61587

Does Migraine Prophylaxis Improve Overactive Bladder Symptoms? Prospective Observational Study

Sinan Eliacık, Aykut Baser, Funda Uysal Tan

Objective: In this study, we aimed to investigate whether there would be any improvement in symptoms of overactive bladder (OAB) after migraine prophylaxis in patients with chronic migraine (CM) and OAB. Materials and Methods: The study group consisted of women aged 19 to 64 years diagnosed as CM according to current International Headache Society (IHS) criteria, and OAB using the OAB-V8 (Overactive Bladder Inquiry Form - V8) and ICIQ-SF (International Consultation on Incontinence Questionnaire Short Form) forms as well as clinical evaluation in the neurology and urology clinics. 63 patients informed and agreed to enter the study were started migraine prophylaxis and evaluated after 6 months for comparison of pre-treatment and post-treatment VPS (visual pain scale), OAB-V8, and the ICIQ-SF scores. Flunarizine, topiramate, venlafaxine and propranolol were used in the treatment of patients. Results: The mean age of 63 women included in the study was 39.15 ± 8.74 (19-64) years. The mean Body Mass Index (BMI) of the patients was determined as 25.41 ± 3.64 (16.4-35.6) kg/m2. After migraine prophylaxis, VPS, OAB-V8 and ICIQ-SF scores decreased significantly in the entire patient group (p

Grand J Urol 2023;3(1):019-025, DOI: 10.5505/GJU.2023.73644

Long-Term Effects of Percutaneous Tibial Nerve Stimulation Treatment for Neurogenic Overactive Bladder Due to Multiple Sclerosis: 24-Month Results

Mehmet Sevim, Sibel Canbaz Kabay, Bekir Aras, Sahin Kabay

Objective: In this study, it was aimed to determine the effectiveness of percutaneous tibial nerve stimulation (PTNS) treatment in neurogenic overactive bladder (NOAB) due to multiple sclerosis (MS) by extending the application interval for 24 months from the beginning. Materials and Methods: Patients completed the PTNS treatment with tapering protocols applied for 6, 9, 12, and 24 months. After 12 weeks of therapy, PTNS was applied at 14 day intervals for 3, at 21 day intervals for 3, and at 28 day intervals for 3 months. The patients completed a 3-day voiding diary at the 3rd, 6th, 9th, 12th, and 24th months. The patients were requested to complete validated questionnaires (ICIQ-SF, OAB-V8, OAB-q SF) within 3-month intervals thereafter during their enrolment in the study. Results: The mean age of 57 patients who completed the PTNS treatment protocol and were included in the study was 42.6 ± 8.2 (23-64) years. Fifteen (26.3%) patients were male and 42 (73.6%) were female. The improvements for all voiding diary parameters were significant at 3rd, 6th, 9th, 12th, and 24th months when compared with the baseline. After 24 months, the daily frequencies of voiding decreased by 6.7 (p

Review Article

Grand J Urol 2021;1(3):133-137, DOI: 10.5222/GJU.2021.43153

The Effects of the Autonomic Nervous System on Urogenital Disorders

Dogukan Sokmen, Yusuf Ilker Comez, Hasan Kerem Alptekin, Ali Veysel Ozden

The possible effect or activity of the autonomic nervous system (ANS) in urogenital disorders is still controversial. Day by day, further studies that have proved the association between chronic urological situations like chronic pelvic pain, premature ejaculation, etc., and autonomic dysfunction have been published. Understanding the actual role of the autonomic nervous system on chronic pelvic disorders will be of interest soon.